Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.

ABSTRACT:

Background

Individuals with type 2 diabetes mellitus are treated with a growing variety of medications targeting multiple metabolic pathways. In recent years, incretins such as the GLP-1 receptor agonists have proven effective in the control of hyperglycemia but also in weight loss, where they are now separately approved as a treatment for obesity. Given the importance of obesity and metabolic syndrome as risk factors for malignancy, the impact of GLP-1 receptor agonists on cancer risk is of increasing interest. Here, we performed an analysis of the impact of GLP-1 receptor agonists and SGLT2 inhibitors on cancer risk and mortality.

Methods

We performed a multicenter retrospective cohort study using the TriNetX database of electronic health records between 2019 and 2024, inc

SUBMITTER: Irons EE 

PROVIDER: S-EPMC12830215 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature